Contrarily, MLN4924 sensitized the function of CDDP, indicating that the drug resistance effect of MLN4924 was specific to BCR::ABL1-targeting TKIs in CML cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.